1. Home
  2. SLN vs BRW Comparison

SLN vs BRW Comparison

Compare SLN & BRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLN
  • BRW
  • Stock Information
  • Founded
  • SLN 1994
  • BRW 1987
  • Country
  • SLN United Kingdom
  • BRW United States
  • Employees
  • SLN N/A
  • BRW N/A
  • Industry
  • SLN Biotechnology: Pharmaceutical Preparations
  • BRW Trusts Except Educational Religious and Charitable
  • Sector
  • SLN Health Care
  • BRW Finance
  • Exchange
  • SLN Nasdaq
  • BRW Nasdaq
  • Market Cap
  • SLN 223.4M
  • BRW 335.1M
  • IPO Year
  • SLN N/A
  • BRW N/A
  • Fundamental
  • Price
  • SLN $4.23
  • BRW $7.67
  • Analyst Decision
  • SLN Buy
  • BRW
  • Analyst Count
  • SLN 5
  • BRW 0
  • Target Price
  • SLN $40.80
  • BRW N/A
  • AVG Volume (30 Days)
  • SLN 282.3K
  • BRW 222.1K
  • Earning Date
  • SLN 02-27-2025
  • BRW 01-01-0001
  • Dividend Yield
  • SLN N/A
  • BRW 15.59%
  • EPS Growth
  • SLN N/A
  • BRW N/A
  • EPS
  • SLN N/A
  • BRW N/A
  • Revenue
  • SLN $43,258,000.00
  • BRW N/A
  • Revenue This Year
  • SLN N/A
  • BRW N/A
  • Revenue Next Year
  • SLN N/A
  • BRW N/A
  • P/E Ratio
  • SLN N/A
  • BRW N/A
  • Revenue Growth
  • SLN 36.71
  • BRW N/A
  • 52 Week Low
  • SLN $4.06
  • BRW $7.15
  • 52 Week High
  • SLN $27.72
  • BRW $8.30
  • Technical
  • Relative Strength Index (RSI)
  • SLN 41.17
  • BRW 35.88
  • Support Level
  • SLN $4.10
  • BRW $7.80
  • Resistance Level
  • SLN $5.23
  • BRW $7.90
  • Average True Range (ATR)
  • SLN 0.40
  • BRW 0.08
  • MACD
  • SLN 0.06
  • BRW -0.02
  • Stochastic Oscillator
  • SLN 33.90
  • BRW 13.49

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.

About BRW Saba Capital Income & Opportunities Fund SBI

Saba Capital Income & Opportunities Fund t is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.

Share on Social Networks: